Roche Holding AG (RHHBY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

You are invited to send in questions for this throughout the entire session using the Q&A functionality of Zoom. In addition to that, you may also raise your virtual hand to address your questions verbally. For participants joining via phone, to raise your hand, use star 9 on your phone's dial pad. When you then get selected to ask your questions, please follow the instructions from the phone and press star 6 to unmute yourself. One last remark, if you'd like to follow the presented slides on your end as well, please feel free to go to www.wolf.com slash investors to download the presentation. At this time, it's my pleasure to introduce you to Thomas Schieneker, CEO of Wolf Group. Mr. Schieneker, the stage is yours. Thank you very much, and good morning, good afternoon, or good evening, wherever you are. I'm really happy to talk to you about our half-year results, which have been extremely strong. So let me kick it off on this slide. So overall, our group sales increased by 7%. So very strong growth by pharma with 10%. In fact, if you look at the momentum in Q2, pharma even grew by 11%. Diagnostics was flat, so very similar to what we saw in the first quarter, and this is purely due to the China healthcare pricing reforms. Without those pricing reforms, diagnostics grew 6% in the first half of the year, so in line with past expectations. But what's even more exciting is the strong bottom-line performance, with core operating profit growing 11%, and thereby our core operating margin increasing by 1.1 percentage points, and core EPS even growing faster at 12%. Also, we want to update our full-year LOE impact guidance, which we are now lowering to $1 billion instead of the $1.2 billion. In the second quarter, we had a number of key milestones. Among others, the EU appro...